Dark

ABUS
Arbutus Biopharma Corporation Common Stock
stock NASDAQ

Market Open

Jul 28, 2026 2:11:40 PM EDT

4.39USD-0.567%(-0.02)297,359

4.38Bid 4.39Ask 0.01Spread

Pre-market

Jul 27, 2026 8:18:30 AM EDT

4.42USD+0.913%(+0.04)0

After-hours

Jul 27, 2026 4:05:30 PM EDT

4.43USD+0.454%(+0.02)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

07:33AM EST Arbutus Announces 2022 Corporate Objectives And Provides Financial Update Benzinga

07:30AM EST Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies GlobeNewswire Inc

Jan 21, 2022

08:08AM EST The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective Benzinga

Jan 4, 2022

07:30AM EST Arbutus to Participate at H.C. Wainwright Bioconnect Virtual GlobeNewswire Inc

Dec 14, 2021

09:51AM EST Arbutus Shares Spike To Session High Following Circulation Of Dec. 7-Dated US Patent & Trademark Office Abstract For Co.'s 'Sterically hindered amines' Benzinga

09:50AM EST CORRECTION: Arbutus Patent Doc Had Incorrect Link In Original Headline; Correct Link Is In Body Of This Headline Benzinga

09:50AM EST BZ NOTE: Arbutus US Patent & Trademark Office Abstract Dated Dec. 7, 2021 Benzinga

09:46AM EST Arbutus Shares Spike To Session High Following Circulation Of US Patent & Trademark Office Abstract For Co.'s 'Sterically hindered amines' Benzinga

07:31AM EST Antios Therapeutics And Arbutus Biopharma Announce First Patient Dosed In Phase 2a Combination Trial Of ATI-2173, AB-729 And Tenofovir Disoproxil Fumarate In Patients With Chronic Hepatitis B Virus Infection Benzinga

07:30AM EST Antios Therapeutics and Arbutus Biopharma Announce First Patient GlobeNewswire Inc

Dec 13, 2021

08:16AM EST Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. RTTNews

07:41AM EST Arbutus, Qilu Pharma Enter Licensing Deal To Develop AB-729 In Mainland China, Hong Kong, Macau And Taiwan RTTNews

07:39AM EST Arbutus To Recieve $40M Upfront Payment From Qilu Pharma for Licensing Agreement to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan Benzinga

07:30AM EST Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets GlobeNewswire Inc

Dec 8, 2021

08:19AM EST Arbutus BioPharma On Tuesday Posted 'Progress Toward A Hepatitis B Cure Combo Therapy' Slide Show Presentation On Its Website; Co. Says Slide Show For Hep DART 2021 Event Benzinga

Dec 7, 2021

07:32AM EST Arbutus Biopharma, X-Chem And Proteros Announce Arbutus Has 'identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease'; Arbutues Achieves Worldwide Exclusive License To Identified Molecules Benzinga

07:30AM EST Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks GlobeNewswire Inc

Dec 2, 2021

01:11PM EST 'Arbutus: Still Plenty of Upside Left Following Favorable Court Decision' -TipRanks Article Benzinga

Dec 1, 2021

02:34PM EST Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet Benzinga

01:49PM EST Why Arbutus Shares Are Soaring Today Benzinga

12:45PM EST Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide Benzinga

12:03PM EST Why Moderna Shares Are Sliding Today Benzinga

12:01PM EST Arbutus Reports Prelim. Data On Co.'s Capsid Inhibitor AB-836 Is Generally Safe, Well Tolerated, Provides Antiviral Activity Benzinga

11:59AM EST Preliminary Data Shows that Arbutus Capsid GlobeNewswire Inc

10:07AM EST Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views Benzinga

09:24AM EST Moderna Loses Appeals Of Board's Rulings On Arbutus Patents Benzinga

Nov 11, 2021

07:30AM EST Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors GlobeNewswire Inc

Nov 10, 2021

07:30AM EST Arbutus to Participate at Jefferies London Healthcare Conference GlobeNewswire Inc

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

07:12AM EST JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $9 Benzinga

Nov 5, 2021

09:31AM EDT Arbutus Biopharma Files For $250M Mixed Shelf Offering Benzinga

Nov 4, 2021

08:28AM EDT Arbutus Biopharma Q3 EPS $(0.24), Inline, Sales $3.34M Beat $2.38M Estimate Benzinga

07:30AM EDT Arbutus Reports Third Quarter 2021 Financial Results and Provides GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 2, 2021

10:23AM EDT Arbutus Announces Late-Breaker Abstract Accepted For Presentation At AASLD - The Liver Meeting 2021 Benzinga

Nov 1, 2021

04:05PM EDT Arbutus Announces Late-Breaker Abstract Accepted for Presentation GlobeNewswire Inc

Oct 21, 2021

07:30AM EDT Arbutus to Report Third Quarter 2021 Financial Results and Provide GlobeNewswire Inc

Oct 18, 2021

06:44AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT). RTTNews

Oct 7, 2021

10:07AM EDT Watching Arbutus Shares As Judge In Moderna v Arbutus Case Will Hear Appeals Thursday Morning Benzinga

06:30AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). RTTNews

Sep 28, 2021

07:35AM EDT Arbutus To Present At Chardan 5th Annual Genetic Medicines Conference Oct. 5, H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference Oct. 13 Benzinga

07:30AM EDT Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences: GlobeNewswire Inc

Sep 21, 2021

07:30AM EDT Arbutus Appoints Lisa M. Caperelli as Vice President, Investor GlobeNewswire Inc

Sep 7, 2021

08:00AM EDT Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire Inc

Aug 30, 2021

01:16PM EDT Watching Airbus; European Patent Office Says Co's '069 Patent Is Inventive (Valid) Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

08:03AM EDT Arbutus Biopharma Q2 EPS $(0.23) Misses $(0.22) Estimate, Sales $2.33M Beat $2.12M Estimate Benzinga

07:30AM EDT New data on AB-729, Arbutus proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress; all AB-729 abstracts selected for best of ILC GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

08:00AM EDT Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire Inc

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 30, 2021

02:02PM EDT Arbutus Biopharma Says Has Received Notice Of Allowance For U.S. Patent Titled 'COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA' Benzinga

Jul 29, 2021

08:00AM EDT Arbutus to Report Second Quarter 2021 Financial Results and GlobeNewswire Inc

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

07:16AM EDT Arbutus Receives Authorization To Proceed With IND For AB-729 In A Phase 2a Clinical Trial RTTNews

07:02AM EDT Arbutus Receives Authorization to Proceed with an Investigational New Drug Application for AB-729, It's Proprietary Subcutaneously-Delivered RNAi Agent Benzinga

07:00AM EDT Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFN-2a in subjects with chronic hepatitis B virus infection (CHB) GlobeNewswire Inc

Jul 6, 2021

04:51PM EDT Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity Benzinga

10:19AM EDT Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B Benzinga

07:10AM EDT Arbutus Biopharma And Vaccitech Agree To Evaluate AB-729 In Combination With VTP-300 For Chronic HBV Infection RTTNews

07:03AM EDT Arbutus Biopharma And Vaccitech Announce Clinical Trial Collaboration Agreement To Evaluate RNAi Therapeutic, AB-729, In Combination With Immunotherapeutic, VTP-300, In Subjects With Chronic Hepatitis B Virus Infection Benzinga

07:00AM EDT Arbutus Biopharma and Vaccitech Announce Clinical Trial GlobeNewswire Inc

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

07:29AM EDT Arbutus Biopharma And Antios Therapeutics Announce Clinical Collaboration Agreement To Evaluate AB-729 In Combination With ATI-2173 In Subjects With Chronic Hepatitis B Virus Infection Benzinga

07:00AM EDT Arbutus Biopharma and Antios Therapeutics Announce Clinical GlobeNewswire Inc

Jun 28, 2021

06:55AM EDT Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate Benzinga

05:49AM EDT Arbutus Biopharma Shares Up 17% Premarket After Company Announced on Saturday Announced Positive Data for its Treatment for Chronic Hepatitis B Benzinga

Jun 26, 2021

07:15AM EDT AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks GlobeNewswire Inc

Jun 3, 2021

10:08AM EDT Arbutus Biopharma US Patent & Trademark Office Abstract For Co.'s 'NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS' Benzinga

Jun 2, 2021

07:34AM EDT Arbutus Announces Multiple Abstracts For Oral And Poster Presentations At EASL 2021 International Liver Congress In June Benzinga

07:30AM EDT Conference Call and Webcast to discuss the new data being presented at EASLscheduled for 8:00 AM ET, Monday, June 28, 2021 GlobeNewswire Inc

May 26, 2021

08:00AM EDT Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming investor conferences: GlobeNewswire Inc

May 5, 2021

07:55AM EDT Arbutus Biopharma Q1 EPS $(0.21) Beats $(0.23) Estimate, Sales $2.11M Miss $3.31M Estimate Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:30AM EDT AB-729, Arbutus proprietary subcutaneously delivered RNAi agent, continues to demonstraterobust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 3, 2021

11:24AM EDT Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company Benzinga

07:06AM EDT Eupraxia Pharma Appoints Bruce Cousins As President & CFO RTTNews

Apr 28, 2021

08:00AM EDT Arbutus to Report First Quarter 2021 Financial Results and Provide GlobeNewswire Inc

Apr 1, 2021

10:08AM EDT Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact Benzinga

07:35AM EDT Arbutus Biopharma, X-Chem And Proteros Biostructures Enter Pan-Coronavirus Discovery Research And License Agreement; Financial Details Not Disclosed Benzinga

07:30AM EDT Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks GlobeNewswire Inc

Mar 16, 2021

07:32AM EDT Arbutus Receives Regulatory Approval To Initiate Phase 1a/1b Clinical Trial With AB-836,An Oral Capsid Inhibitor For Treatment Of Chronic Hepatitis B Infection Benzinga

07:30AM EDT Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b GlobeNewswire Inc

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

08:10AM EST Recap: Arbutus Biopharma Q4 Earnings Benzinga

07:37AM EST Arbutus Biopharma Reports FY20 Sales $6.914M Up From $6.011M YoY Benzinga

07:30AM EST AB-729, Arbutus proprietary subcutaneously delivered RNAi agent, demonstratesrobust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data GlobeNewswire Inc

04:07AM EST Earnings Scheduled For March 4, 2021 Benzinga

Mar 3, 2021

10:42AM EST Earnings Preview: Arbutus Biopharma Benzinga

Mar 2, 2021

08:00AM EST Arbutus to Participate at H.C. Wainwright Global Life Sciences GlobeNewswire Inc

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

11:52AM EST Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection Benzinga

07:38AM EST Assembly Bipsciences, Arbutus Biopharma Initiate Phase 2 Clinical Trial Of Triple Combination Therapy For Treatment Of Chronic Hepatits B Virus Benzinga

07:30AM EST Trial will evaluate Assemblys core inhibitor candidate, vebicorvir, with Arbutus RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy GlobeNewswire Inc

Feb 22, 2021

08:00AM EST Arbutus to Report Fourth Quarter and Year End 2020 Financial GlobeNewswire Inc

Jan 25, 2021

07:38AM EST Arbutus Announces 2021 Corporate Objectives And Provides Financial Update Benzinga

07:30AM EST 2021 objectives leverage positive momentum in Arbutus Hepatitis B research and development programs GlobeNewswire Inc

Jan 4, 2021

08:00AM EST Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright GlobeNewswire Inc

Dec 17, 2020

10:17AM EST Benzinga's Top Upgrades, Downgrades For December 17, 2020 Benzinga

06:41AM EST H.C. Wainwright Initiates Coverage On Arbutus Biopharma with Buy Rating, Announces Price Target of $10 Benzinga

Dec 10, 2020

07:31AM EST Arbutus Biopharma Reports Added Clinical Data From Ongoing Phase 1a/1b Trial With AB-729 For Chronic Hepatitis B Subjects: 'Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of 1.37 log10' Benzinga

07:30AM EST Repeat dosing of 60 mg AB-729 every 8 weeks resulted inmean HBsAg declines of 1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (1.44 log10, N=7, p<0.7) GlobeNewswire Inc

Nov 16, 2020

03:33PM EST Arbutus Biopharma shares were trading higher after the company said it will advance its AB-729 into a phase 2 study. Benzinga

07:14AM EST UPDATE: Arbutus Says 'Results support advancement into Phase 2 combination clinical trials with AB-729 dosing as infrequently as every 8 or 12 weeks' Benzinga

07:13AM EST Arbutus Announces Additional HBsAg Decline Data With AB-729 In Chronic Hepatitis B Subjects; Reports 'Repeat dosing of 60 mg AB-729 every 4 weeks resulted in robust and continuous mean declines in HBsAg decline at week 20' Benzinga

07:00AM EST Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 GlobeNewswire Inc

Nov 15, 2020

02:40PM EST Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted GlobeNewswire Inc

Nov 10, 2020

08:00AM EST Arbutus to Present at Jefferies Virtual London Healthcare Conference GlobeNewswire Inc

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:51AM EST Arbutus Biopharma Q3 EPS $(0.27) Misses $(0.22) Estimate, Sales $1.52M Miss $1.66M Estimate Benzinga

07:30AM EST Results from an ongoing Phase 1a/1b clinical trial for Arbutus AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

09:21AM EST Return On Capital Employed Overview: Arbutus Biopharma Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:00AM EDT Arbutus to Report Third Quarter 2020 Financial Results and Provide GlobeNewswire Inc

Oct 13, 2020

08:00AM EDT Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright GlobeNewswire Inc

Sep 28, 2020

08:00AM EDT Arbutus to Participate in Virtual Fireside Chat at GlobeNewswire Inc

Sep 15, 2020

07:46AM EDT Arbutus Reports AB-729 90mg Single-Dose Week 12 Data In Chronic Hep C Subjects Showed Significant, Continuous Reductions In HBsAg Benzinga

07:30AM EDT Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safetyand tolerability profile GlobeNewswire Inc

Sep 9, 2020

08:00AM EDT Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright GlobeNewswire Inc

Aug 27, 2020

08:07AM EDT Assembly Biosciences And Arbutus Biopharma Announce Clinical Collaboration Agreement To Evaluate The Combination Of Core Inhibitor ABI-H0731 With RNAi Therapeutic AB-729 In Patients With Chronic Hepatitis B Virus Infection Benzinga

08:00AM EDT Assembly Biosciences and Arbutus Biopharma Announce Clinical GlobeNewswire Inc

Aug 12, 2020

11:27AM EDT ROCE Insights For Arbutus Biopharma Benzinga

Aug 7, 2020

07:50AM EDT Recap: Arbutus Biopharma Q2 Earnings Benzinga

07:33AM EDT Arbutus Biopharma Reports Phase 1A/1B Clinical Trial For AB-729 Remains On Track With Results From Additional Cohorts Expected In The Second Half Of 2020 Benzinga

07:32AM EDT Arbutus Biopharma Q2 EPS $(0.25) Misses $(0.24) Estimate, Sales $1.51M Miss $1.74M Estimate Benzinga

07:30AM EDT Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For August 7, 2020 Benzinga

Aug 5, 2020

08:00AM EDT Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire Inc

Jul 29, 2020

08:00AM EDT Arbutus to Report Second Quarter 2020 Financial Results GlobeNewswire Inc

Jul 27, 2020

09:17PM EDT Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development Benzinga

11:05AM EDT Arbutus Biopharma shares are trading higher on continued volatility after a patent court last week ruled in Arbutus' favor and against Moderna. Benzinga

Jul 26, 2020

10:38PM EDT Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development Benzinga

Jul 24, 2020

03:59PM EDT Arbutus Biopharma Option Alert: Sep 18 $7.5 Calls at the Ask: 693 @ $1.0 vs 473 OI; Earnings 8/7 Before Open [est] Ref=$4.9165 Benzinga

11:50AM EDT How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program Benzinga

11:27AM EDT Arbutus Biopharma shares are trading higher after a patent court ruled in Arbutus' favor and against Moderna. UPDATE: Shares have since reversed, now lower. Benzinga

11:25AM EDT How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program Benzinga

10:32AM EDT Stocks That Hit 52-Week Highs On Friday Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Open Lower; Honeywell Tops Q2 Estimates Benzinga

10:13AM EDT Shares of Arbutus Biopharma Corp. (ABUS) gained over 25% on Friday morning after the U.S. Patent and Trademark Office ruled in favor of the company in a patent dispute with Moderna Inc. (MRNA) RTTNews

08:09AM EDT Benzinga Pro's Top 5 Stocks To Watch For Fri., Jul. 24, 2020: ABUS, EBAY, HAS, BLNK, FFIV Benzinga

06:12AM EDT UPDATE: Patent Trial, Appeal Board Says Arbutus Entitled To Receive Tiered Low Single Digit Royalties On Future Sales Of Genevant Products Covered By Licensed Patents Benzinga

06:11AM EDT Arbutus Biopharma 8-K Confirms US PTO Doc Which Was Circulated Thurs Afternoon; Shows US PTO Patent Trial, Appeal board Gave Decision In Moderna Challenge Of '609 Patent Validity, PTAB Determined No Challenged Claims Patentable Benzinga

05:09AM EDT Baird Downgrades Arbutus Biopharma to Neutral Benzinga

12:03AM EDT Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent Benzinga

Jul 23, 2020

01:37PM EDT Arbutus Biopharma Shares Spike Higher, Co. Files For Confidential Treatment With SEC Benzinga

Jul 20, 2020

01:48PM EDT Arbus Biopharma Shares Spike Higher After Traders Circulate Scribd Link Titled 'ABUS - A Hidden Gem in COVID' Benzinga

05:11AM EDT 80 Biggest Movers From Friday Benzinga